Moderna, COVID-19
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians
Why Australia could miss out on Moderna's new COVID-19 vaccine
While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the government seemingly only intends to make one available to the public.
Health Canada approves Moderna’s COVID-19 vaccine targeting latest variant
The KP.3 variant of SARS-CoV-2 is dominating in Canada right now, accounting for the majority of the COVID-19 cases in the country.
Moderna Shares Rise on Canada Government Approval of Updated Covid-19 Vaccine
Shares of Moderna rose after the company said that the government of Canada authorized its updated Covid-19 vaccine, joining the U.S. in the approval. The stock was up 4.5% at $72.28 in Tuesday afternoon trading, becoming the best performing stock of the S&P 500 and Nasdaq 100. The stock has, however, dropped 26% since the beginning of the year.
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine.Moderna's Spikevax KP.2 targets the KP.2 variant of the virus.The U.S. Food and Drug Administration has also approved the shot,
Moderna's updated COVID-19 vaccine approved in Canada
Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax formula targets the KP.2 subvariant, one of the latest offshoots of the Omicron variant of the virus that causes COVID-19.
Be warned: Check your insurance before getting a COVID-19 vaccine this year
For those who are uninsured or under-insured, CDPH will have vaccine at its three CDPH Immunization Clinics. Walk-ins are ...
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
Nikkei Asia9d
Moderna to launch skin cancer vaccine as soon as 2025: CEO
NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...
CBC.ca4d
Moderna's updated COVID-19 vaccine for 2024-25 approved in Canada
Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall immunization campaigns. The federal vaccine portal lists approval of Moderna's product. Provinces and ...
France 2411d
Moderna mRNA mpox vaccine shows promise in animal study
An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...